Endologix, Inc.  

(Public, NASDAQ:ELGX)   Watch this stock  
Find more results for James Abraham, Esq
14.03
-0.03 (-0.18%)
Real-time:   10:12AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.95 - 14.13
52 week 10.29 - 18.07
Open 14.06
Vol / Avg. 21,841.00/701,849.00
Mkt cap 946.22M
P/E     -
Div/yield     -
EPS -0.73
Shares 67.42M
Beta 1.17
Inst. own 103%
Aug 3, 2015
Q2 2015 Endologix Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 3, 2015
Q2 2015 Endologix Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 2, 2015
Endologix Inc at Jefferies Global Healthcare Conference
May 28, 2015
Endologix Inc Annual Shareholders Meeting
May 13, 2015
Endologix Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Endologix Inc at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -30.58% -21.97%
Operating margin -26.62% -14.38%
EBITD margin - -17.51%
Return on average assets -18.51% -12.85%
Return on average equity -37.61% -28.34%
Employees 590 -
CDP Score - -

Address

2 Musick
IRVINE, CA 92618-1631
United States - Map
+1-949-5957200 (Phone)
+1-949-6999622 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Company’s EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.

Officers and directors

John McDermott Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Robert D. Mitchell President
Age: 53
Bio & Compensation  - Reuters
Shelley B. Thunen Chief Financial Officer and Corporate Secretary
Age: 62
Bio & Compensation  - Reuters
Todd G. Abraham Vice President - Operations
Age: 50
Bio & Compensation  - Reuters
Joseph A. DeJohn Vice President - Sales
Age: 54
Bio & Compensation  - Reuters
David M. Jennings Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Amanda L. DePalma Vice President - Global Marketing
Age: 43
Bio & Compensation  - Reuters
Jose A. Lima Vice President - Quality
Age: 49
Bio & Compensation  - Reuters
Charles Love Vice President - Clinical Affairs
Age: 52
Bio & Compensation  - Reuters
James E. Machek Vice President - Research and Development
Age: 57
Bio & Compensation  - Reuters